Arsenic trioxide: An emerging therapy for multiple myeloma

被引:51
作者
Munshi, NC [1 ]
机构
[1] Univ Arkansas Med Sci, Hematol Oncol Sect, Little Rock, AR 72205 USA
关键词
arsenic trioxide; multiple myeloma; antiangiogenesis; apoptosis;
D O I
10.1634/theoncologist.6-suppl_2-17
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Arsenic trioxide can inhibit proliferation and induce apoptosis in multiple myeloma (MM) cells in vitro and in vivo. In addition to affecting tumor growth, arsenic trioxide has been shown to inhibit angiogenesis, suggesting that it may have significant potency in the treatment of MM. Based on these observations, the clinical efficacy of arsenic trioxide was evaluated in patients with advanced refractory MM using a fixed-dose intravenous infusion given daily for a maximum of 60 days. Nine patients were evaluable. All nine had extensive prior therapy; seven had two or more high-dose chemotherapy cycles with autologous stem cell support. All nine patients had cytogenetic abnormalities, and six had chromosome 13 deletions. Of the four patients who completed more than 30 days of arsenic trioxide infusion, two had >50% reduction in myeloma paraprotein, one had stable disease, and one progressed. Of the five patients with <30 days infusion, two had stable disease and three progressed. Thus, on an intent-to-treat basis, two of nine (23%) patients responded (>50% paraprotein reduction). The regimen was well tolerated except for development of cytopenia, which responded to G-CSF, and a grade III pulmonary complication in one patient. In summary, arsenic trioxide has activity in end-stage, high-risk myeloma and deserves further evaluation in earlier-stage disease.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 24 条
[1]   Standard therapy versus autologous transplantation in multiple myeloma [J].
Attal, M ;
Harousseau, JL .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) :133-&
[2]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[3]   Long-term follow-up after high-dose therapy for high-risk multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Naucke, S ;
Mattox, S ;
Bracy, D ;
Crowley, J ;
Tricot, G ;
Alexanian, R .
BONE MARROW TRANSPLANTATION, 1998, 21 (11) :1101-1107
[4]   Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism [J].
Chauhan, D ;
Pandey, P ;
Ogata, A ;
Teoh, G ;
Treon, S ;
Urashima, M ;
Kharbanda, S ;
Anderson, KC .
ONCOGENE, 1997, 15 (07) :837-843
[5]  
Desikan R, 2000, BLOOD, V95, P4008
[6]  
Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011
[7]   High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial [J].
Fermand, JP ;
Ravaud, P ;
Chevret, S ;
Divine, M ;
Leblond, V ;
Belanger, C ;
Macro, M ;
Pertuiset, E ;
Dreyfus, F ;
Mariette, X ;
Boccacio, C ;
Brouet, JC .
BLOOD, 1998, 92 (09) :3131-3136
[8]   COMBINATION CHEMOTHERAPY VERSUS MELPHALAN AND PREDNISOLONE IN THE TREATMENT OF MULTIPLE-MYELOMA - AN OVERVIEW OF PUBLISHED TRIALS [J].
GREGORY, WM ;
RICHARDS, MA ;
MALPAS, JS .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :334-342
[9]  
Kyle RA, 1999, CURR PRACT MED, V2, P1131
[10]  
MCELWAIN TJ, 1983, LANCET, V2, P822